Found: 10
Select item for more details and to access through your institution.
Retraction Note: Atrial natriuretic peptide protects against cisplatin‑induced granulocytopenia.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Bioequivalence, food effect and comparative pharmacokinetics of SUVN-1105, a novel granule formulation of abiraterone acetate, to Zytiga in healthy male subjects.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2024, v. 93, n. 3, p. 253, doi. 10.1007/s00280-023-04629-1
- By:
- Publication type:
- Article
Parthenolide inhibits the proliferation and migration of cervical cancer cells via FAK/GSK3β pathway.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2024, v. 93, n. 3, p. 203, doi. 10.1007/s00280-023-04621-9
- By:
- Publication type:
- Article
Enhanced anticancer synergy of LOM612 in combination with selinexor: FOXO1 nuclear translocation-mediated inhibition of Wnt/β-catenin signaling pathway in breast cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2024, v. 93, n. 3, p. 191, doi. 10.1007/s00280-023-04618-4
- By:
- Publication type:
- Article
Prognostic value of RRM1 and its effect on chemoresistance in pancreatic cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2024, v. 93, n. 3, p. 237, doi. 10.1007/s00280-023-04616-6
- By:
- Publication type:
- Article
Retraction Note: Induction of apoptosis by [6]-gingerol associated with the modulation of p53 and involvement of mitochondrial signaling pathway in B[a]P-induced mouse skin tumorigenesis.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Effect of vitamin E on doxorubicin and paclitaxel-induced memory impairments in male rats.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2024, v. 93, n. 3, p. 215, doi. 10.1007/s00280-023-04602-y
- By:
- Publication type:
- Article
Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2024, v. 93, n. 3, p. 177, doi. 10.1007/s00280-023-04600-0
- By:
- Publication type:
- Article
Polatuzumab vedotin pharmacokinetics in a hemodialysis patient with diffuse large B-cell lymphoma.
- Published in:
- 2024
- By:
- Publication type:
- Case Study
A phase-II study based on dose adjustment according to UGT1A1 polymorphism: is irinotecan underdosed in first-line FOLFIRI regimen for mCRC?
- Published in:
- Cancer Chemotherapy & Pharmacology, 2024, v. 93, n. 3, p. 225, doi. 10.1007/s00280-023-04603-x
- By:
- Publication type:
- Article